title: Bone mass and body composition of adult women with congenital virilizing 21-hydroxylase deficiency after glucocorticoid treatment since infancy.
abstract: OBJECTIVE
  To study bone mass, body composition and androgenic/anabolic activity in adult women with virilizing congenital adrenal hyperplasia (CAH) treated with glucocorticoids since infancy and to relate this to the postmenarcheal glucocorticoid impact.
  
  
  METHODS
  Thirteen adult women with virilizing CAH treated with gluco- and mineralocorticoids but otherwise medicine-free were investigated with respect to bone mineral content, body composition by dual energy X-ray absorptiometry and endocrine status. In addition an index of accumulated postmenarcheal exogenous glucocorticoid impact was calculated. Seven of the patients had regular menstrual periods, and six were oligomenorrheic but responded with withdrawal bleedings on cyclic progestagens. The data for the patients were compared with those of age-matched healthy reference subjects.
  
  
  RESULTS
  In spite of their shorter stature, CAH patients were significantly heavier and had a significantly higher body mass index and fat/lean body mass ratio than the controls. Their bone mineral area density (BMD) was significantly lower than that of the controls. Serum concentrations of androgens were subnormal in all except two of the patients. Strong negative associations were found between BMD and the calculated index of accumulated postmenarcheal glucocorticoid dose but not between BMD and circulating androgen levels.
  
  
  CONCLUSIONS
  The results indicate that glucocorticoids were administered in excess in most of the patients, resulting in subnormal levels of adrenocortical androgens, increased body fat and bone demineralization. Increased catabolic activity due to hypercortisolism rather than decreased androgenic/anabolic steroids is probably the major cause of the subnormal BMD in the treated CAH patients.
authors.affiliation: Departments of Woman and Child Health and Diagnostic Radiology, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden.
authors.forename: K
authors.initials: K
authors.lastname: Hagenfeldt
authors.forename: E
authors.initials: E
authors.lastname: Martin Ritzén
authors.forename: H
authors.initials: H
authors.lastname: Ringertz
authors.forename: J
authors.initials: J
authors.lastname: Helleday
authors.forename: K
authors.initials: K
authors.lastname: Carlström
mesh_terms: D015502:Absorptiometry, Photon; D000312:Adrenal Hyperplasia, Congenital / Q000188:drug therapy* / Q000473:pathology*; D000328:Adult; D001823:Body Composition / Q000187:drug effects / Q000502:physiology*; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000473:pathology*; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006728:Hormones / Q000097:blood; D006801:Humans
chemical_list: D005938:Glucocorticoids; D006728:Hormones